RESUMEN
Background: This open-label, phase III trial compared chemoradiation followed by surgery with or without neoadjuvant and adjuvant cetuximab in patients with resectable esophageal carcinoma. Patients and methods: Patients were randomly assigned (1 : 1) to two cycles of chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2) followed by chemoradiation (45 Gy, docetaxel 20 mg/m2 and cisplatin 25 mg/m2, weekly for 5 weeks) and surgery, with or without neoadjuvant cetuximab 250 mg/m2 weekly and adjuvant cetuximab 500 mg/m2 fortnightly for 3 months. The primary end point was progression-free survival (PFS). Results: In total, 300 patients (median age, 61 years; 88% male; 63% adenocarcinoma; 85% cT3/4a, 90% cN+) were assigned to cetuximab (n = 149) or control (n = 151). The R0-resection rate was 95% for cetuximab versus 97% for control. Postoperative treatment-related mortality was 6% in both arms. Median PFS was 2.9 years [95% confidence interval (CI), 2.0 to not reached] with cetuximab and 2.0 years (95% CI, 1.5-2.8) with control [hazard ratio (HR), 0.79; 95% CI, 0.58-1.07; P = 0.13]. Median overall survival (OS) time was 5.1 years (95% CI, 3.7 to not reached) versus 3.0 years (95% CI, 2.2-4.2) for cetuximab and control, respectively (HR, 0.73; 95% CI, 0.52-1.01; P = 0.055). Time to loco-regional failure after R0-resection was significantly longer for cetuximab (HR 0.53; 95% CI, 0.31-0.90; P = 0.017); time to distant failure did not differ between arms (HR, 1.01; 95% CI, 0.64-1.59, P = 0.97). Cetuximab did not increase adverse events in neoadjuvant or postoperative settings. Conclusion: Adding cetuximab to multimodal therapy significantly improved loco-regional control, and led to clinically relevant, but not-significant improvements in PFS and OS in resectable esophageal carcinoma. Clinical trial information: NCT01107639.
Asunto(s)
Adenocarcinoma/terapia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/terapia , Quimioradioterapia/mortalidad , Neoplasias Esofágicas/terapia , Esofagectomía/mortalidad , Terapia Neoadyuvante/mortalidad , Adenocarcinoma/patología , Anciano , Carcinoma de Células Escamosas/patología , Cetuximab/administración & dosificación , Cisplatino/administración & dosificación , Terapia Combinada , Docetaxel/administración & dosificación , Neoplasias Esofágicas/patología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Tasa de SupervivenciaRESUMEN
Background: HER2-targeted therapy plus chemotherapy is standard treatment in advanced HER2+ breast cancer. Trastuzumab alone followed by addition of chemotherapy at disease progression versus upfront combination therapy has not been elucidated. Patients and methods: One-hundred seventy-five patients with measurable/evaluable HER2+ advanced disease without previous HER2-directed therapy were randomized to trastuzumab alone followed, at disease progression, by the combination with chemotherapy (Arm A) or upfront trastuzumab plus chemotherapy (Arm B). Chemotherapy could be stopped after ≥6 cycles in responding patients, trastuzumab was continued until progression. The primary endpoint of this superiority trial was time to progression (TTP) on combined trastuzumab-chemotherapy (Combination-TTP) in both arms. Secondary endpoints included response rate, TTP, overall survival, quality of life and toxicity. Results: Combination-TTP was longer than expected in both arms, 12.2 months in Arm A and 10.3 months in Arm B and not significantly different (hazard ratio [HR] 0.7; 95% CI 0.5-1.1; P =0.1). Overall survival was also not significantly different (HR 0.9; 95% CI 0.6-1.5; P = 0.55). In Arm A, the median TTP before introduction of chemotherapy was 3.7 months (95% CI 2.3-5.4), yet at 2 years 6% of patients were still on trastuzumab alone. Patients without visceral disease had a Combination-TTP of 21.8 months in arm A, compared with 10.1 months in arm B (unplanned analysis HR 2.1, 95% CI 1.1-4.2, P = 0.03). Patients with visceral disease showed no difference. Toxicity was chemotherapy-related. Conclusion: The outcome of patients receiving sequential trastuzumab-chemotherapy or upfront combination was similar. We failed to demonstrate superiority of the sequential approach. These results nevertheless suggest chemotherapy and its toxicity can be deferred, especially in patients with indolent, non-visceral disease. Despite a larger non-inferiority confirmatory study would be needed, these findings represent an additional proof of concept that de-escalation strategies can be discussed in individual patients.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Óseas/tratamiento farmacológico , Neoplasias de la Mama/tratamiento farmacológico , Adulto , Anciano , Antraciclinas/administración & dosificación , Biomarcadores de Tumor/metabolismo , Neoplasias Óseas/mortalidad , Neoplasias Óseas/secundario , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/patología , Quimioterapia Adyuvante , Supervivencia sin Enfermedad , Femenino , Humanos , Estimación de Kaplan-Meier , Persona de Mediana Edad , Modelos de Riesgos Proporcionales , Receptor ErbB-2/metabolismo , Trastuzumab/administración & dosificación , Resultado del TratamientoRESUMEN
BACKGROUND: Fluorouracil-based adjuvant chemotherapy in gastric cancer has been reported to be effective by several meta-analyses. Perioperative chemotherapy in locally advanced resectable gastric cancer (RGC) has been reported improving survival by two large randomized trials and recent meta-analyses but the role of neoadjuvant chemotherapy and optimal regimen remains to be determined. We compared a neoadjuvant with adjuvant docetaxel-based regimen in a prospective randomized phase III trial, of which we present the 10-year follow-up data. PATIENTS AND METHODS: Patients with cT3-4 anyN M0 or anyT cN1-3 M0 gastric carcinoma, staged with endoscopic ultrasound, computed tomography, bone scan, and laparoscopy, were assigned to receive four 21-day/cycles of docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1, and fluorouracil 300 mg/m(2)/day over days 1-14, either before (arm A) or after (arm B) gastrectomy. Event-free survival was the primary end point, whereas secondary end points included overall survival, toxicity, down-staging, pathological response, quality of life, and feasibility of adjuvant chemotherapy. RESULTS: This trial was activated in November 1999 and closed in November 2005 due to insufficient accrual. Of the 70 enrolled patients, 69 were randomized, 34 to arm A and 35 to arm B. No difference in EFS (2.5 years in both arms) or OS (4.3 versus 3.7 years, in arms A and B, respectively) was found. A higher dose intensity of chemotherapy was observed in arm A and more frequent chemotherapy-related serious adverse events occurred in arm B. Surgery was safe after preoperative chemotherapy. A 12% pathological complete response was observed in arm A. CONCLUSION: Docetaxel/cisplatin/fluorouracil chemotherapy is promising in preoperative setting of locally advanced RGC. The early stopping could mask the real effectiveness of neoadjuvant treatment. However, the complete pathological tumour responses, feasibility, and safe surgery warrant further investigation of a taxane-based regimen in the preoperative setting.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Terapia Neoadyuvante , Neoplasias Gástricas/tratamiento farmacológico , Adenocarcinoma/patología , Adenocarcinoma/cirugía , Adolescente , Adulto , Anciano , Cisplatino/administración & dosificación , Supervivencia sin Enfermedad , Docetaxel , Fluorouracilo/administración & dosificación , Gastrectomía , Humanos , Persona de Mediana Edad , Periodo Perioperatorio , Periodo Posoperatorio , Neoplasias Gástricas/patología , Neoplasias Gástricas/cirugía , Taxoides/administración & dosificación , Resultado del TratamientoRESUMEN
BACKGROUND: Patients with advanced, incurable cancer receiving anticancer treatment often experience multidimensional symptoms. We hypothesize that real-time monitoring of both symptoms and clinical syndromes will improve symptom management by oncologists and patient outcomes. PATIENTS AND METHODS: In this prospective multicenter cluster-randomized phase-III trial, patients with incurable, symptomatic, solid tumors, who received new outpatient chemotherapy with palliative intention, were eligible. Immediately before the weekly oncologists' visit, patients completed the palm-based E-MOSAIC assessment (Edmonton-Symptom-Assessment-Scale, ≤3 additional symptoms, estimated nutritional intake, body weight change, Karnofsky Performance Status, medications for pain, fatigue, nutrition). A cumulative, longitudinal monitoring sheet (LoMoS) was printed immediately. Eligible experienced oncologists were defined as one cluster each and randomized to receive the immediate print-out LoMoS (intervention) or not (control). Primary analysis limited to patients having uninterrupted (>4/6 visits with same oncologist) patient-oncologist sequences was a mixed model for the difference in patients global quality of life (G-QoL; items 29/30 of EORTC-QlQ-c30) between baseline (BL) and week 6. Intention-to-treat (ITT) analysis included all eligible patients. RESULTS: In 8 centers, 82 oncologists treated 264 patients (median 66 years; overall survival intervention 6.3, control 5.4 months) with various tumors. The between-arm difference in G-QoL of 102 uninterrupted patients (intervention: 55; control: 47) was 6.8 (P = 0.11) in favor of the intervention; in a sensitivity analysis (oncologists treating ≥2 patients; 50, 39), it was 9.0 (P = 0.07). ITT analysis revealed improvement in symptoms (difference last study visit-BL: intervention -5.4 versus control 2.1, P = 0.003) and favored the intervention for communication and coping. More patients with high symptom load received immediate symptom management (chart review, nurse-patient interview) by oncologists getting the LoMoS. CONCLUSION: Monitoring of patient symptoms, clinical syndromes and their management clearly reduced patients' symptoms, but not QoL. Our results encourage the implementation of real-time monitoring in the routine workflow of oncologist with a computer solution.
Asunto(s)
Monitoreo Ambulatorio/métodos , Neoplasias/patología , Cuidados Paliativos/métodos , Evaluación de Síntomas/métodos , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Toma de Decisiones Clínicas , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/terapia , Pacientes Ambulatorios , Estudios Prospectivos , Calidad de Vida , Encuestas y CuestionariosRESUMEN
BACKGROUND: Chemotherapy plus bevacizumab is a standard option for first-line treatment in metastatic colorectal cancer (mCRC) patients. We assessed whether no continuation is non-inferior to continuation of bevacizumab after completing first-line chemotherapy. PATIENTS AND METHODS: In an open-label, phase III multicentre trial, patients with mCRC without disease progression after 4-6 months of standard first-line chemotherapy plus bevacizumab were randomly assigned to continuing bevacizumab at a standard dose or no treatment. CT scans were done every 6 weeks until disease progression. The primary end point was time to progression (TTP). A non-inferiority limit for hazard ratio (HR) of 0.727 was chosen to detect a difference in TTP of 6 weeks or less, with a one-sided significance level of 10% and a statistical power of 85%. RESULTS: The intention-to-treat population comprised 262 patients: median follow-up was 36.7 months. The median TTP was 4.1 [95% confidence interval (CI) 3.1-5.4] months for bevacizumab continuation versus 2.9 (95% CI 2.8-3.8) months for no continuation; HR 0.74 (95% CI 0.58-0.96). Non-inferiority could not be demonstrated. The median overall survival was 25.4 months for bevacizumab continuation versus 23.8 months (HR 0.83; 95% CI 0.63-1.1; P = 0.2) for no continuation. Severe adverse events were uncommon in the bevacizumab continuation arm. Costs for bevacizumab continuation were estimated to be â¼30,000 USD per patient. CONCLUSIONS: Non-inferiority could not be demonstrated for treatment holidays versus continuing bevacizumab monotheray, after 4-6 months of standard first-line chemotherapy plus bevacizumab. Based on no impact on overall survival and increased treatment costs, bevacizumab as a single agent is of no meaningful therapeutic value. More efficient treatment approaches are needed to maintain control of stabilized disease following induction therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, number NCT00544700.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Bevacizumab/administración & dosificación , Camptotecina/administración & dosificación , Camptotecina/análogos & derivados , Neoplasias Colorrectales/mortalidad , Neoplasias Colorrectales/patología , Femenino , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Humanos , Irinotecán , Leucovorina/administración & dosificación , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/secundario , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Compuestos Organoplatinos/administración & dosificación , Oxaliplatino , Pronóstico , Estudios Prospectivos , Tasa de Supervivencia , Adulto JovenRESUMEN
OBJECTIVES: Molecular subclassification of non small-cell lung cancer (NSCLC) is essential to improve clinical outcome. This study assessed the prognostic and predictive value of circulating micro-RNA (miRNA) in patients with non-squamous NSCLC enrolled in the phase II SAKK (Swiss Group for Clinical Cancer Research) trial 19/05, receiving uniform treatment with first-line bevacizumab and erlotinib followed by platinum-based chemotherapy at progression. MATERIALS AND METHODS: Fifty patients with baseline and 24 h blood samples were included from SAKK 19/05. The primary study endpoint was to identify prognostic (overall survival, OS) miRNA's. Patient samples were analyzed with Agilent human miRNA 8x60K microarrays, each glass slide formatted with eight high-definition 60K arrays. Each array contained 40 probes targeting each of the 1347 miRNA. Data preprocessing included quantile normalization using robust multi-array average (RMA) algorithm. Prognostic and predictive miRNA expression profiles were identified by Spearman's rank correlation test (percentage tumor shrinkage) or log-rank testing (for time-to-event endpoints). RESULTS: Data preprocessing kept 49 patients and 424 miRNA for further analysis. Ten miRNA's were significantly associated with OS, with hsa-miR-29a being the strongest prognostic marker (HR=6.44, 95%-CI 2.39-17.33). Patients with high has-miR-29a expression had a significantly lower survival at 10 months compared to patients with a low expression (54% versus 83%). Six out of the 10 miRNA's (hsa-miRN-29a, hsa-miR-542-5p, hsa-miR-502-3p, hsa-miR-376a, hsa-miR-500a, hsa-miR-424) were insensitive to perturbations according to jackknife cross-validation on their HR for OS. The respective principal component analysis (PCA) defined a meta-miRNA signature including the same 6 miRNA's, resulting in a HR of 0.66 (95%-CI 0.53-0.82). CONCLUSION: Cell-free circulating miRNA-profiling successfully identified a highly prognostic 6-gene signature in patients with advanced non-squamous NSCLC. Circulating miRNA profiling should further be validated in external cohorts for the selection and monitoring of systemic treatment in patients with advanced NSCLC.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas/genética , Carcinoma de Pulmón de Células no Pequeñas/patología , Perfilación de la Expresión Génica , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patología , MicroARNs/genética , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Monoclonales Humanizados/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bevacizumab , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Terapia Combinada , Progresión de la Enfermedad , Clorhidrato de Erlotinib , Femenino , Expresión Génica , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/mortalidad , Masculino , MicroARNs/sangre , Persona de Mediana Edad , Estadificación de Neoplasias , Platino (Metal)/administración & dosificación , Pronóstico , Estudios Prospectivos , Quinazolinas/administración & dosificación , Reproducibilidad de los Resultados , Factores de RiesgoRESUMEN
BACKGROUND: The risk of osteoporosis and fracture influences the selection of adjuvant endocrine therapy. We analyzed bone mineral density (BMD) in Swiss patients of the Breast International Group (BIG) 1-98 trial [treatment arms: A, tamoxifen (T) for 5 years; B, letrozole (L) for 5 years; C, 2 years of T followed by 3 years of L; D, 2 years of L followed by 3 years of T]. PATIENTS AND METHODS: Dual-energy X-ray absorptiometry (DXA) results were retrospectively collected. Patients without DXA served as control group. Repeated measures models using covariance structures allowing for different times between DXA were used to estimate changes in BMD. Prospectively defined covariates were considered as fixed effects in the multivariable models. RESULTS: Two hundred and sixty-one of 546 patients had one or more DXA with 577 lumbar and 550 hip measurements. Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and smoking. Treatment did not influence the occurrence of osteoporosis (T score < -2.5 standard deviation). CONCLUSIONS: All aromatase inhibitor regimens reduced BMD. The sequential schedules were as detrimental for bone density as L monotherapy.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Densidad Ósea/efectos de los fármacos , Neoplasias de la Mama/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Femenino , Cadera/diagnóstico por imagen , Cadera/patología , Humanos , Letrozol , Vértebras Lumbares/diagnóstico por imagen , Vértebras Lumbares/patología , Persona de Mediana Edad , Análisis Multivariante , Nitrilos/administración & dosificación , Osteoporosis/inducido químicamente , Osteoporosis/diagnóstico por imagen , Posmenopausia , Radiografía , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Retrospectivos , Tamoxifeno/administración & dosificación , Triazoles/administración & dosificaciónRESUMEN
BACKGROUND: The continuation of trastuzumab beyond progression in combination with capecitabine as secondary chemotherapy for HER2-positive metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase in toxicity. PATIENTS AND METHODS: A Markov cohort simulation was used to follow the clinical course of typical patients with MBC. Information on response rates and major adverse effects was derived, and transition probabilities were estimated, based on the results of the Breast International Group 03-05 clinical trial. Direct costs were assessed from the perspective of the Swiss health care system. RESULTS: The addition of trastuzumab to capecitabine is estimated to cost on average an additional of 33,980 and to yield a gain of 0.35 quality-adjusted life years (QALYs), resulting in an incremental cost-effectiveness ratio of 98,329/QALYs gained. Probabilistic sensitivity analysis showed that the willingness-to-pay threshold of 60,000/QALY was reached in 12% of cases. CONCLUSION: The addition of trastuzumab to capecitabine in MBC patients is more expensive than what is typically regarded as cost-effective but falls within the value ranges found for established regimens in the treatment of MBC.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/economía , Análisis Costo-Beneficio/economía , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales Humanizados , Neoplasias de la Mama/mortalidad , Capecitabina , Costos y Análisis de Costo , Desoxicitidina/administración & dosificación , Desoxicitidina/análogos & derivados , Progresión de la Enfermedad , Femenino , Fluorouracilo/administración & dosificación , Fluorouracilo/análogos & derivados , Humanos , Metástasis Linfática , Cadenas de Markov , Pronóstico , Años de Vida Ajustados por Calidad de Vida , Sensibilidad y Especificidad , Tasa de Supervivencia , Factores de Tiempo , TrastuzumabRESUMEN
BACKGROUND: To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination with capecitabine as first-line treatment of metastatic colorectal cancer. PATIENTS AND METHODS: We carried out a randomized phase II trial to select one of the following treatment regimens for further investigation: weekly irinotecan at a dose of 70 mg/m(2) days 1, 8, 15, 22, 29 (arm A) or 3-weekly irinotecan at a dose of 300/240 mg/m(2) day 1 and days 22 (arm B) in combination with capecitabine 1000 mg/m(2) twice daily days 1-14 and days 22-35 every 6 weeks. RESULTS: Seventy-five patients with good performance status entered the trial. The two arms were well balanced for relevant patient and disease characteristics. The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%). Other grade 3/4 toxic effects were rare (<5%). Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B. Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months. Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients. CONCLUSIONS: The primary end point of this study was the objective response rate and based on the statistical design of the trial, the 3-weekly irinotecan schedule was selected over weekly irinotecan administration. The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience, but the study was not designed to detect differences in these parameters. In addition, tumor response was shown to have a beneficial effect on QoL indicators.
Asunto(s)
Antimetabolitos Antineoplásicos/uso terapéutico , Antineoplásicos Fitogénicos/uso terapéutico , Camptotecina/análogos & derivados , Camptotecina/uso terapéutico , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/patología , Desoxicitidina/análogos & derivados , Desoxicitidina/uso terapéutico , Adulto , Anciano , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/efectos adversos , Antineoplásicos Fitogénicos/administración & dosificación , Antineoplásicos Fitogénicos/efectos adversos , Camptotecina/administración & dosificación , Camptotecina/efectos adversos , Capecitabina , Desoxicitidina/administración & dosificación , Desoxicitidina/efectos adversos , Esquema de Medicación , Femenino , Fluorouracilo/análogos & derivados , Humanos , Infusiones Intravenosas , Irinotecán , Masculino , Persona de Mediana Edad , Calidad de Vida , Resultado del TratamientoRESUMEN
The present study investigates whether there is a relationship between subjective well-being and the change of immune markers in HIV-infected subjects. Twenty-one HIV-infected persons completed questionnaires. Immune markers (CD4-percentage and CD4/CD8-ratio) were measured at the beginning of the study, after 8 months and after 15 months. In a hierarchical multiple regression model, baseline values of immune markers explained most of the variance of the immune markers, both after 8 and 15 months. After including several control variables in the model, depression values and the values on the symptom checklist explained an additional increment of variance of both immune markers after eight months. Therefore, data of the present study suggest that predominantly depressive feelings co-determine immune status in HIV-infected persons.
Asunto(s)
Recuento de Linfocito CD4 , Relación CD4-CD8 , Depresión/psicología , Infecciones por VIH/psicología , Adulto , Depresión/inmunología , Femenino , Infecciones por VIH/inmunología , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Inventario de Personalidad , Estudios Prospectivos , Psiconeuroinmunología , Rol del EnfermoRESUMEN
The aim of the present survey was to evaluate the incidence and spectrum of complementary therapies among HIV-infected persons in Switzerland. Under the auspices of the SATG (Swiss Aids Treatment Group), a 13-page questionnaire was created to gather data on socio-demographics, stage of HIV infection, current regimes on opportunistic infections and antiretroviral medication, current and past use of complementary treatments, and reasons for choosing and terminating complementary therapies. Approximately 640 questionnaires in French and German were distributed among HIV-infected subjects. Distributing organizations were People with Aids (P.W.A.), the University Hospital Zurich and the regional "Aids-Hilfe" institutions. With 129 questionnaires returned, the feedback was about 20%. More than 80% of participants used at least one complementary therapy. Each person currently used four therapies (median) from a spectrum of more than 60 specific complementary treatments. The following treatments were used by more than 25% of respondents: vitamins, special diets, food supplements, physical exercise, meditation, phytotherapy, homeopathy, and psychotherapy. 47% of participants took either antiretroviral medication, prophylaxis against opportunistic infections, or both.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/terapia , Terapias Complementarias/estadística & datos numéricos , Infecciones por VIH/terapia , Terapias Complementarias/métodos , Femenino , Humanos , Masculino , Suiza , Resultado del TratamientoRESUMEN
The professional activity of air traffic controllers (ATC) is often considered to be rather stressful. Certain characteristics of this job are likely to produce stress; for example an ATC can not predict when a situation becomes critical and he is not able to regulate the workload. In order to assess psychophysiological stress reactions in this working situation, saliva samples were taken from 158 male air traffic controllers before and after each of two working sessions. In contrast to the expected immunosuppressive effects, the working sessions caused a marked increase in the concentration and secretion rate of salivary immunoglobulin A (sIgA), as well as in the concentration of salivary cortisol. The increase in sIgA, however, was not correlated with the salivary cortisol response or with the amount of actual or perceived workload, whereas the cortisol response was correlated with both workload measures. It is suggested that positive emotional engagement is responsible for the observed sIgA increase and that measuring this physiological response may be a valuable tool for differentiating between positive and negative stress effects or between successful and unsuccessful adaptation or coping with situational demands.
Asunto(s)
Aeronaves , Nivel de Alerta/fisiología , Hidrocortisona/sangre , Inmunoglobulina A/sangre , Estrés Psicológico/complicaciones , Carga de Trabajo/psicología , Adaptación Psicológica/fisiología , Adulto , Humanos , Masculino , Persona de Mediana Edad , Psiconeuroinmunología , Psicofisiología , Saliva/inmunologíaRESUMEN
The present study was designed to investigate whether there is a consistent response in ongoing EEG due to repetitive olfactory stimulation. Two odors of different hedonic quality were presented bilaterally to five male subjects at suprathreshold levels. A room-air blank served as the control stimulus. Each odor was presented six times to each subject in each of three sessions. Electrocortical activity, heart rate, skin conductance and breathing cycle were recorded continuously. EEG variables assessed were difference scores of absolute power in the frequency bands theta, alpha 1, alpha 2 and beta 1 at eight locations. Phenylethyl alcohol was rated pleasant, while valeric acid was judged unpleasant. Within 8 s after stimulus release, valeric acid increased alpha 2 power, whereas phenylethyl alcohol did not. No further frequency bands were affected by olfactory stimulation. These findings suggest that smelling an unpleasant odor leads to a cortical deactivation.
Asunto(s)
Sistema Nervioso Autónomo/fisiología , Corteza Cerebral/fisiología , Electroencefalografía , Odorantes , Olfato/fisiología , Adulto , Respuesta Galvánica de la Piel/fisiología , Frecuencia Cardíaca/fisiología , Humanos , Masculino , Ácidos Pentanoicos/farmacología , Alcohol Feniletílico/farmacología , Mecánica Respiratoria/fisiologíaRESUMEN
The present study was designed to test the hypothesis that varying sensory input can affect mood, autonomic arousal, and electrocortical activity. Twenty right-handed males were exposed to three rhythmic audio-visual stimulation programs, with either a high intensity and variety of stimuli (program H), a low stimulation (program L) or with a transient from high to low (program HL). Multichannel EEG, heart rate, and skin conductance were recorded continuously, and after each trial mood was rated on a bipolar adjective list. EEG data were subjected to FFT dipole approximation procedure, and dipole locations and field strength (Global Field Power) were analyzed for the frequency bands theta, alpha, and beta 1. Mood ratings clearly differed between programs H and HL, with highest values of arousal after H. Programs L and HL decreased autonomic arousal, whereas H induced deactivating as well as activating effects. Field strength of the alpha band decreased similarly during all programs. Dipole sources were located more to the left in the alpha band and more to the right in the beta 1 band during all programs as compared with baseline. Therefore, programs affected mood and autonomic variables differently, but not electrocortical variables. The higher activation of the right hemisphere during all programs is interpreted as an indication that audio-visual stimulation does induce changes in the brain, such as are commonly found in altered states of consciousness.
Asunto(s)
Estimulación Acústica , Sistema Nervioso Autónomo/fisiología , Electroencefalografía , Estimulación Luminosa , Adulto , Afecto/fisiología , Ritmo alfa , Nivel de Alerta/fisiología , Lateralidad Funcional/fisiología , Respuesta Galvánica de la Piel/fisiología , Frecuencia Cardíaca/fisiología , Humanos , Masculino , Relajación/fisiología , Ritmo TetaRESUMEN
The present study was designed to test the effectiveness of an optical-acoustic mind machine (brain machine) in inducing relaxation. The mind machine used in this study stimulates the user with flickers of light and pulsating sounds. During the treatment the stimulation decreases from 10 to 2 hertz and increases again at half time. No other relaxation inducing effects were used. Sixteen subjects received two or three sessions of instruction with the mind machine. Afterwards the parameters listed below were continuously recorded during one session with the mind machine and one session with the presentation of relaxing environmental sounds, which was conducted one week later: Frontal EMG, SCL on the left hand, heart rate. Pre- and posttreatment samples of saliva were collected and assessed for salivary IgA (S-IgA) and salivary cortisol (S-cortisol). Changes in the subjects' self-report were measured with a bipolar adjective list. ANCOVA with repeated measures revealed a decrease for all electrophysiological parameters during the mind machine session. S-cortisol concentration decreases as S-IgA increases. The mind machine made the subjects feel warmer and calmer. The results of this with in design revealed no reliable differences between the mind machine and the relaxing sounds of nature on the physiological and self-esteem parameters. The significantly greater decrease of SCL during the mind machine session was due to the elevated baseline of this parameter. The results lead to the conclusion that the mind machine seems to be useful in inducing relaxation, but is no more effective than the relaxing nature sounds used in this study.